Q4 Results: AstraZeneca Pharma Shares Down 7% Profit Drops Despite Strong Revenue Growth

Mumbai, May 27:Shares of AstraZeneca Pharma India declined as much as 7% on Wednesday after the company reported a fall in fourth-quarter profit despite posting healthy revenue growth.

AstraZeneca Pharma India share price slid as investors reacted to margin pressure and a rise in expenses, overshadowing the company’s strong top-line performance. As of writingthis story, the stock was down 5% at Rs 8,520.

AstraZeneca Pharma India reported a 23% year-on-year decline in net profit to ₹44.88 crore for the March quarter, compared with ₹58.25 crore in the corresponding period last year.

Revenue Growth Remains Strong

Despite the decline in profit, the company posted robust growth in revenue from operations.

Quarterly revenue rose over 20% year-on-year to ₹578.61 crore, supported by continued momentum in its oncology and biopharmaceutical segments, along with progress in the rare disease portfolio.

The stock declined as expenses ate into the topline scaring investors. Source: NSE

For the full financial year FY26, AstraZeneca Pharma India reported a 62% jump in net profit to ₹187.52 crore, while total revenue climbed more than 32% to ₹2,275.58 crore.

The company attributed the growth to sustained demand across key therapies and continued expansion in speciality treatments.

Rising Expenses Hurt Margins

Investor sentiment, however, remained cautious after the company’s total expenses surged sharply during the quarter.

Total expenses rose more than 27% year-on-year to ₹525.34 crore, outpacing revenue growth and weighing on profitability. Analysts pointed to pressure on operating margins as one of the key reasons behind the decline in earnings.

Market participants also noted that pharmaceutical stocks have recently seen heightened sensitivity to margin trends and cost pressures, especially in speciality and branded therapies where operational spending remains elevated.

Pharma Sector Remains in Focus

The decline in AstraZeneca Pharma India shares comes at a time when the broader pharmaceutical sector continues to remain under investor focus amid mixed quarterly earnings trends.

While revenue growth across the sector has largely remained healthy, rising input costs, marketing expenditure and regulatory-related spending have pressured margins for several companies.

Despite Wednesday’s decline, analysts continue to view AstraZeneca Pharma India as a key player in the oncology and specialty pharma space given its strong product portfolio and growing presence in high-value therapies.

Investors are now expected to closely monitor the company’s margin trajectory, future product launches and growth in speciality treatments for further cues on the stock.

Source:

• https://www.nseindia.com/get-quote/equity/ASTRAZEN/AstraZeneca-Pharma-India-Limited